James Crowe

Eleven current Vanderbilt University faculty members, 10 of whom are investigators at Vanderbilt University Medical Center, are included in the 2024 list of “Highly Cited Researchers” around the world whose papers have been cited most frequently by other scientists. Read More

Jens Meiler, Distinguished Research Professor of Chemistry, was named the principal investigator for the project, in cooperation with 14 investigators across eight institutions. The team will work together to use advanced technology, including computational modeling, AI-driven predictions and structural biology, to develop a groundbreaking vaccine against all alphaviruses that offers long-lasting protection. Read More

Jad Abumrad, Distinguished Research Professor of Communication of Science and Technology and creator of Vanderbilt’s Quantum Potential series, talks to Vanderbilt Magazine about this groundbreaking project, described as a collection of wild but precise portraits of the scholars, scientists and students at Vanderbilt who are finding new ways to understand the world—and change it. Read More

Twelve current investigators at Vanderbilt University Medical Center and Vanderbilt University are on this year’s list of scientists whose papers have been cited the most frequently by other researchers. Read More

Vanderbilt's James E. Crowe, Jr, MD, and Neil Osheroff, PhD, are among 12 individuals honored by the Association of American Medical Colleges during its 2023 Awards Recognition Event. Read More

WATCH: Today’s fight against infectious diseases is being waged in the computer lab as much as the wet lab. Using artificial intelligence and machine learning, Vanderbilt researchers and students like School of Engineering undergraduate Karen Pu are expanding the power of computer modeling to identify mutating viruses—and potentially improve vaccines. Read More

Quantum Potential is a collection of wild but precise portraits of the scholars, scientists and students at Vanderbilt who are finding new ways to understand the world—and change it. A premiere event will take place Oct. 11 at 6 p.m., including a screening of two short films, behind-the-scenes discussions and an immersive performance. The event is open the general public; registration is required. Read More

Two Vanderbilt faculty who conducted translational research have received the distinction of Best Invention of 2022 from TIME magazine. TIME’s Best Inventions of 2022 Cover “These winning innovations exemplify the transformative potential of university research when it aims to solve society’s most urgent problems, and when universities partner with the broader innovation ecosystem to bring... Read More

Two Vanderbilt faculty who conducted translational research have received the distinction of Best Invention of 2022 from TIME magazine. TIME’s Best Inventions of 2022 Cover “These winning innovations exemplify the transformative potential of university research when it aims to solve society’s most urgent problems, and when universities partner with the broader innovation ecosystem to bring... Read More

Vanderbilt Vaccine Center researchers have isolated monoclonal antibodies against hantaviruses, an emerging source of human disease with pandemic potential. Read More

The discovery of monoclonal antibodies that neutralize Rift Valley Fever Virus — an emerging infection with pandemic potential — lays the foundation for future therapeutic antibody development. Read More

The isolation of human monoclonal antibodies against dangerous viruses including EEEV, Hendra and Nipah could offer new ways to treat and prevent these infections. Read More

AstraZeneca is advancing into phase 3 clinical trials with an investigational COVID-19 therapy of two long-acting antibodies discovered by Vanderbilt University Medical Center and optimized by AstraZeneca. Read More

Based on positive results in preclinical studies reported today, potently neutralizing antibodies identified by researchers at Vanderbilt University Medical Center are showing promise as a potential therapy for preventing and treating COVID-19. Read More

Researchers at Vanderbilt University Medical Center, Purdue University and the University of Wisconsin-Madison have isolated human monoclonal antibodies that potentially can prevent a rare but devastating polio-like illness in children linked to a respiratory viral infection. Read More

From the front lines of patient care to collaborating with scientists across the globe searching for treatments and vaccines, Vanderbilt University Medical Center and Vanderbilt University researchers have been working for months to combat the COVID-19 pandemic. Read More

Vanderbilt Vaccine Center team isolates monoclonal antibodies against the mosquito-borne Ross River virus, which causes rash, fever and debilitating muscle and joint pain lasting three to six months. Read More

Monoclonal antibodies against Marburg virus — a more lethal cousin of the RNA virus that causes COVID-19 — may aid in the development of antibody "cocktails" to counter viral infection. Read More

VUMC scientists are redoubling their efforts to help people fight off bird flu. Their focus is H7N9, one of the most dangerous of the influenza viruses that have been transmitted from birds to humans. Read More

The flu mutates so quickly that we need a new vaccine every year, but Vanderbilt scientists have found a vulnerable part of the virus that doesn't mutate as much. Read More